JP2025511847A5 - - Google Patents

Info

Publication number
JP2025511847A5
JP2025511847A5 JP2024559386A JP2024559386A JP2025511847A5 JP 2025511847 A5 JP2025511847 A5 JP 2025511847A5 JP 2024559386 A JP2024559386 A JP 2024559386A JP 2024559386 A JP2024559386 A JP 2024559386A JP 2025511847 A5 JP2025511847 A5 JP 2025511847A5
Authority
JP
Japan
Prior art keywords
diffraction pattern
ray
crystal morphology
measured
ranifibranol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024559386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511847A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2023/058743 external-priority patent/WO2023194339A1/en
Publication of JP2025511847A publication Critical patent/JP2025511847A/ja
Publication of JP2025511847A5 publication Critical patent/JP2025511847A5/ja
Pending legal-status Critical Current

Links

JP2024559386A 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態 Pending JP2025511847A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22305456.0 2022-04-05
EP22305456 2022-04-05
PCT/EP2023/058743 WO2023194339A1 (en) 2022-04-05 2023-04-04 Crystalline form of lanifibranor

Publications (2)

Publication Number Publication Date
JP2025511847A JP2025511847A (ja) 2025-04-16
JP2025511847A5 true JP2025511847A5 (cg-RX-API-DMAC7.html) 2026-04-08

Family

ID=81326293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024559386A Pending JP2025511847A (ja) 2022-04-05 2023-04-04 ラニフィブラノールの結晶形態

Country Status (14)

Country Link
US (1) US20250243192A1 (cg-RX-API-DMAC7.html)
EP (1) EP4504725A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025511847A (cg-RX-API-DMAC7.html)
KR (1) KR20250002337A (cg-RX-API-DMAC7.html)
CN (1) CN119301120A (cg-RX-API-DMAC7.html)
AR (1) AR128985A1 (cg-RX-API-DMAC7.html)
AU (1) AU2023250118A1 (cg-RX-API-DMAC7.html)
CA (1) CA3247273A1 (cg-RX-API-DMAC7.html)
IL (1) IL316075A (cg-RX-API-DMAC7.html)
MX (1) MX2024012348A (cg-RX-API-DMAC7.html)
PY (1) PY2324870A (cg-RX-API-DMAC7.html)
TW (1) TW202404966A (cg-RX-API-DMAC7.html)
UY (1) UY40216A (cg-RX-API-DMAC7.html)
WO (1) WO2023194339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325334A1 (en) * 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof
JP2026501899A (ja) 2023-01-19 2026-01-16 インベンティバ ラニフィブラノール製剤
WO2024251730A1 (en) 2023-06-05 2024-12-12 Inventiva Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition
AR133887A1 (es) * 2023-09-22 2025-11-12 Inventiva Método de fabricación de lanifibranor
IL330214A (en) 2023-12-21 2026-08-01 Inventiva Combination therapy for the prevention and/or treatment of liver disease
AU2024409290A1 (en) 2023-12-21 2026-08-06 Inventiva Combination therapy for the prevention and/or the treatment of a liver disease
WO2025191292A1 (en) 2024-03-15 2025-09-18 Inventiva Methods and monitoring of treatment with lanifibranor
WO2025191117A1 (en) 2024-03-15 2025-09-18 Inventiva Prevention of blood disorders in patient treated with a ppar agonist
TW202604485A (zh) 2024-05-17 2026-02-01 法商因文帝華公司 患有肝損傷患者肝疾病之治療
WO2026115290A1 (en) 2024-11-28 2026-06-04 Inventiva Non-invasive monitoring of nash treatment with lanifibranor
WO2026125286A1 (en) 2024-12-09 2026-06-18 Inventiva Combinations comprising lanifibranor and a glp-1/gip/glucagon triple receptor agonist for use in the treatment of liver diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890071B1 (fr) 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
WO2022143479A1 (zh) 2020-12-29 2022-07-07 广东东阳光药业有限公司 一种化合物的固体形式及其制备方法和用途
US20240246949A1 (en) 2021-06-10 2024-07-25 Teva Pharmaceuticals International Gmbh Solid state forms of lanifibranor and process for preparation thereof
CN115466252A (zh) 2021-06-11 2022-12-13 上海希迈医药科技有限公司 一种Lanifibranor的晶型及其制备方法
AU2022325334A1 (en) 2021-08-12 2024-02-22 Inventiva Crystal form of lanifibranor, preparation method therefor, and use thereof

Similar Documents

Publication Publication Date Title
JP5714824B2 (ja) 1−4−(5−シアノインドール−3−イル)ブチル−4−(2−カルバモイルベンゾフラン−5−イル)ピペラジン塩酸塩の多形相
JP2009537603A (ja) 5−アミノ−3−(2’,3’−ジ−O−アセチル−ベータ−D−リボフラノシル)−3H−チアゾロ[4,5−d]ピリミジン−2−オンのマレイン酸塩のA型及びB型結晶形
ES2351958T3 (es) 5-cloro-3-(4-metanosulfonilfenil)-6'-metil-[2,3'] bipiridinil en forma cristalina pura y procedimiento de síntesis.
CN103539795A (zh) 阿哌沙班的多晶型及其制备方法
JP2012507496A (ja) レナリドマイドの結晶形およびその調製方法
JP2024521412A5 (cg-RX-API-DMAC7.html)
AU2001264804A1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis
JP2008539258A5 (cg-RX-API-DMAC7.html)
JP2024095561A5 (cg-RX-API-DMAC7.html)
CN119301120A (zh) 拉尼兰诺的晶型
JP2025536416A5 (cg-RX-API-DMAC7.html)
KR102657147B1 (ko) 빌라스틴의 결정형 및 그의 제조 방법
CN110862389A (zh) 一种阿哌沙班晶型的制备方法
EA020545B1 (ru) Соли карбоновой кислоты 2-амино-3-карбэтоксиамино-6-(4-фторбензиламино)пиридина
US6673935B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
JP2024542840A5 (cg-RX-API-DMAC7.html)
CN111592485A (zh) 盐酸替罗非班及其游离碱的晶型及其制备方法
JP2022540678A5 (cg-RX-API-DMAC7.html)
WO2013013595A1 (zh) 一种17α-乙酰氧基-11β-(4-N,N-二甲氨基苯基)-19-去甲孕甾-4,9-二烯-3,20-二酮的结晶物及其制备方法
WO2008092327A1 (fr) Cristaux demi-hydratés de voglibose, leur procédé de préparation, et préparation pharmaceutique les contenant
JP2023521631A5 (cg-RX-API-DMAC7.html)
JP2023523165A5 (cg-RX-API-DMAC7.html)
CN111278828A (zh) 巴瑞替尼磷酸盐的新晶型及其制备方法
JP2012503641A (ja) アカンプロセートカルシウムの多形体
WO2025176138A1 (zh) 亮氨酸二肽的盐